Hormone Use in Menopause and Male Andropause : A Choice for Women and Men: A Choice for Women and Men (Google eBook)
Sheldon J. Segal Population Council, Division of Human Reproduction Luigi Mastroianni Jr. Professor, Department of Obstetrics and Gynecology University of Pennsylvania School of Medicine
Oxford University Press, Oct 4, 2003 - Medical - 224 pages
This book, by two of the most distinguished figures in fertility and reproduction research, answers all the most common questions about menaupause and andropause, and hormone resupplement therapy (HRT) for menopausal women. It offers explanations of all aspects of this subject, presenting balanced and reliable information about benefits, risks, and prospects for this field. Segal invented Norplant, the first long-term implantable contraceptive, and as the leader of Reproductive Biology at the Population Council, he orchestrated and coordinated the research and trials leading to basically every new contraceptive introduced over a period of about 25 years. Mastroianni did more than anyone else to develop in vitro fertizilation as a viable treatment option, and was for many years the chairman of the largest department of obstetrics and gynecology, and the director of the most successful IVF clinic. This book is unique in including coverage of the climacteric in men.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Why do women have menopause?
What are the signs of menopause?
What is menopausal hormone therapy?
Why should women consider hormone therapy?
Riskbenefit ratio Making the choice
Can HT protect brain function and prevent Alzheimers disease?
Does the approach of menopause mean the end of fertility?
Herbal products for menopause
Why should men consider androgen supplementation therapy?
What are the AST choices for men?
The first designer androgen for men
Can men safely use AST?
Should aging men use nonprescription androgens?
Sex and the aging man
Can AST help brain function in aging men?
Questions about menopause
aging Alzheimer's disease anabolic androgen receptors andropause androstenedione benefits blood body bone density bone mineral density brain function breast cancer cardiovascular cause cells changes cholesterol Clin Endocrinol Metab clinical trials cognitive function controlled cycle decline decrease Dehydroepiandrosterone DHEA dihydrotestosterone dose drug Endocrinol Metab 84 endometrium estro estrogen receptor evaluated factors fertility follicles gland hormone replacement hormone therapy hot flashes improvement increase libido lipid liver long-term male menopausal hormone therapy menopausal symptoms menopausal women menstrual MENT normal older oral osteoporosis ovarian ovary ovulation partial androgen deficiency perimenopausal phytoestrogens pills pituitary placebo postmenopausal women pregnancy Premarin Prempro prescription prevent progestin prostate protein raloxifene replacement therapy reported reproductive scientific SERMs serum sexual function sperm steroids stimulation tamoxifen testis testoster testosterone testosterone levels testosterone supplementation tion tissues transdermal treatment uterus vaginal dryness WHI study woman Women's Health Initiative
Page 170 - Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Page 170 - Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.
Page 170 - Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial.